POST Online Media Lite Edition



 

NEWLY REPORTED COVID-19 CASES (11.19.2021, 4:50pm CEST, WHO):   India 11,106    Brazil 11,977    United Kingdom 46,858    Russia 37,156    Turkey 22,234    France 19,840    Argentina 1,553    Germany 52,970    Spain 3,932    Columbia 2,257    Italy 10,645    Mexico 3,836    Ukraine 20,050    Poland 23,242    Philippines 1,297    Malaysia 6,380    Netherlands 23,680    Peru 1,370    Thailand 6,855    Czechia 13,374    Canada 2,448    Romania 3,076    Chile 2,611    Serbia 3,219    Sweden 1,210    Portugal 2,398    Vietnam 10,223    Kazakhstan 1,272    Austria 14,212    Hungary 11,289    Greece 7,276    Georgia 4,278    Bulgaria 2,785    Belarus 1,844    Slovakia 7,418    Azerbaijan 2,124    Croatia 7,270    Bolivia 1,119    Ireland 4,646    Lithuania 1,847    Denmark 4,013    South Korea 3,034    Slovenia 3,662    Latvia 1,221    Laos 1,401    China 31    New Zealand 200    Australia 1,302   

FDA approves drugs that cure hepatitis C

Staff Writer |
The U.S. Food and Drug Administration has approved two drugs to treat hepatitis C infection in children aged 12 and older.

Article continues below






Both Solvaldi (sofosbuvir) and Harvoni (ledipasvir, sofosbuvir) are already approved for use in adults, the agency said.

The medications are antivirals that prevent the hepatitis C virus (HCV) from reproducing. "In most cases, they cure HCV," the FDA added.

"These approvals will help change the landscape for HCV treatment by addressing an unmet need in children and adolescents," said Dr. Edward Cox, director of the Office of Antimicrobial Products in the FDA's Center for Drug Evaluation and Research.

Hepatitis C causes liver inflammation that can lead to liver failure. Between 3 and 4 million people in the United States are infected with the virus, the agency said.

Children born to infected mothers are at higher risk of being infected, the FDA said, noting there are an estimated 23,000 to 46,000 children in the United States with hepatitis C.

In clinical studies, the most common side effects of both drugs were fatigue and headache.

People taking hepatitis C antivirals who are also infected with hepatitis B have a greater risk of serious liver problems or death. This can happen because the hepatitis B virus can be reactivated if patients are not also taking antivirals to stem the hepatitis B infection.

Harvoni and Sovaldi are marketed by Gilead Sciences Inc., in Foster City, Calif.


What to read next

Nearly 90% of Coloradans diagnosed with Hepatitis C go untreated
New hepatitis C drugs might eliminate disease
Hepatitis becomes number one cause of death in world